Skip Nav Destination
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura
von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Issue Archive
Table of Contents
DRUG ADVANCES
STIMULUS REPORT
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents
Clinical Trials & Observations
Andishe Attarbaschi,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Oussama Abla,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Leila Ronceray,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Shweta Bansil,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Simon Bomken,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Birgit Burkhardt,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Francesco Ceppi,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Alan K. S. Chiang,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Hema Dave,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Alina Fedorova,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Michael Henry,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Janez Jazbec,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Edita Kabickova,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Rishi S. Kotecha,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Jelena Lazic,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Jan Loeffen,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Natalia Miakova,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Tomoo Osumi,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Marta Pillon,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Apostolos Pourtsidis,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Charlotte Rigaud,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Gevorg Tamamyan,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Sneha Tandon,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Anne Uyttebroeck,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Jamie Verdu-Amoros,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Wilhelm Woessmann,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Grazyna Wrobel,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology,Lisa Giulino-Roth,on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma, the International Berlin-Frankfurt-Münster Study Group, and selected North American Centers of Pediatric Hematology and Oncology
CLINICAL TRIALS AND OBSERVATIONS
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Clinical Trials & Observations
Francine Garnache-Ottou,Chrystelle Vidal,Sabeha Biichlé,Florian Renosi,Eve Poret,Maïder Pagadoy,Maxime Desmarets,Anne Roggy,Estelle Seilles,Lou Soret,Françoise Schillinger,Sandrine Puyraimond,Tony Petrella,Claude Preudhomme,Christophe Roumier,Elisabeth A. MacIntyre,Véronique Harrivel,Yohan Desbrosses,Bérengère Gruson,Franck Geneviève,Sylvain Thepot,Yuriy Drebit,Thibaut Leguay,François-Xavier Gros,Nicolas Lechevalier,Pascale Saussoy,Véronique Salaun,Edouard Cornet,Zehaira Benseddik,Richard Veyrat-Masson,Orianne Wagner-Ballon,Célia Salanoubat,Marc Maynadié,Julien Guy,Denis Caillot,Marie-Christine Jacob,Jean-Yves Cahn,Rémy Gressin,Johann Rose,Bruno Quesnel,Estelle Guerin,Franck Trimoreau,Jean Feuillard,Marie-Pierre Gourin,Adriana Plesa,Lucile Baseggio,Isabelle Arnoux,Norbert Vey,Didier Blaise,Romaric Lacroix,Christine Arnoulet,Blandine Benet,Véronique Dorvaux,Caroline Bret,Bernard Drenou,Agathe Debliquis,Véronique Latger-Cannard,Caroline Bonmati,Marie-Christine Bene,Pierre Peterlin,Michel Ticchioni,Pierre-Simon Rohrlich,Anne Arnaud,Stefan Wickenhauser,Valérie Bardet,Sabine Brechignac,Benjamin Papoular,Victoria Raggueneau,Jacques Vargaftig,Rémi Letestu,Daniel Lusina,Thorsten Braun,Vincent Foissaud,Jérôme Tamburini,Hind Bennani,Nicolas Freynet,Catherine Cordonnier,Magali Le Garff-Tavernier,Nathalie Jacques,Karim Maloum,Damien Roos-Weil,Didier Bouscary,Vahid Asnafi,Ludovic Lhermitte,Felipe Suarez,Etienne Lengline,Frédéric Féger,Giorgia Battipaglia,Mohamad Mohty,Sabrina Bouyer,Ouda Ghoual,Elodie Dindinaud,Caroline Basle,Mathieu Puyade,Carinne Lafon,Thierry Fest,Mikael Roussel,Xavier Cahu,Elsa Bera,Sylvie Daliphard,Fabrice Jardin,Lydia Campos,Françoise Solly,Denis Guyotat,Anne-Cécile Galoisy,Alice Eischen,Caroline Mayeur-Rousse,Blandine Guffroy,Christian Recher,Marie Loosveld,Alice Garnier,Vincent Barlogis,Maria Alessandra Rosenthal,Sophie Brun,Nathalie Contentin,Sébastien Maury,Mary Callanan,Christine Lefebvre,Natacha Maillard,Patricia Okamba,Christophe Ferrand,Olivier Adotevi,Philippe Saas,Fanny Angelot-Delettre,Delphine Binda,Eric Deconinck
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
Clinical Trials & Observations
Caner Saygin,Ashwin Kishtagari,Ryan D. Cassaday,Natalie Reizine,Ilana Yurkiewicz,Michaela Liedtke,Wendy Stock,Richard A. Larson,Ross L. Levine,Martin S. Tallman,Jae H. Park,Cassandra Kerr,Bartlomiej Przychodzen,Mikkael A. Sekeres,Matt E. Kalaycio,Hetty E. Carraway,Betty K. Hamilton,Ronald Sobecks,Aaron Gerds,Sudipto Mukherjee,Aziz Nazha,Jaroslaw P. Maciejewski,Anjali S. Advani
MYELOID NEOPLASIA
Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML
Silvia Masciarelli,Ernestina Capuano,Tiziana Ottone,Mariadomenica Divona,Serena Lavorgna,Francesca Liccardo,Martyna Śniegocka,Serena Travaglini,Nelida I. Noguera,Alessandra Picardi,Vincenzo Petrozza,Alessandro Fatica,Luca Tamagnone,Maria Teresa Voso,Francesco Lo Coco,Francesco Fazi
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation
Alexandra M. Stevens,Michael Xiang,Lisa N. Heppler,Isidora Tošić,Kevin Jiang,Jaime O. Munoz,Amos S. Gaikwad,Terzah M. Horton,Xin Long,Padmini Narayanan,Elizabeth L. Seashore,Maci C. Terrell,Raushan Rashid,Michael J. Krueger,Alicia E. Mangubat-Medina,Zachary T. Ball,Pavel Sumazin,Sarah R. Walker,Yoshimasa Hamada,Seiichi Oyadomari,Michele S. Redell,David A. Frank
Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes
Frederic Picou,Christine Vignon,Christelle Debeissat,Sébastien Lachot,Olivier Kosmider,Nathalie Gallay,Amelie Foucault,Marie-Hélène Estienne,Noémie Ravalet,Marie C. Bene,Jorge Domenech,Emmanuel Gyan,Michaela Fontenay,Olivier Herault
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
Clinical Trials & Observations
Michele Baccarani,Elisabetta Abruzzese,Vincenzo Accurso,Francesco Albano,Mario Annunziata,Sara Barulli,Germana Beltrami,Micaela Bergamaschi,Gianni Binotto,Monica Bocchia,Giovanni Caocci,Isabella Capodanno,Francesco Cavazzini,Michele Cedrone,Marco Cerrano,Monica Crugnola,Mariella D’Adda,Chiara Elena,Carmen Fava,Paola Fazi,Claudio Fozza,Sara Galimberti,Valentina Giai,Antonella Gozzini,Gabriele Gugliotta,Alessandra Iurlo,Gaetano La Barba,Luciano Levato,Alessandro Lucchesi,Luigia Luciano,Francesca Lunghi,Monia Lunghi,Michele Malagola,Roberto Marasca,Bruno Martino,Angela Melpignano,Maria Cristina Miggiano,Enrico Montefusco,Caterina Musolino,Fausto Palmieri,Patrizia Pregno,Davide Rapezzi,Giovanna Rege-Cambrin,Serena Rupoli,Marzia Salvucci,Rosaria Sancetta,Simona Sica,Raffaele Spadano,Fabio Stagno,Mario Tiribelli,Simona Tomassetti,Elena Trabacchi,Massimiliano Bonifacio,Massimo Breccia,Fausto Castagnetti,Fabrizio Pane,Domenico Russo,Giuseppe Saglio,Simona Soverini,Paolo Vigneri,Gianantonio Rosti
PLATELETS AND THROMBOPOIESIS
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura
Clinical Trials & Observations
Jingrui Sui,Wenjing Cao,Konstantine Halkidis,Mohammad S. Abdelgawwad,Nicole K. Kocher,Bryan Guillory,Lance A. Williams,Radhika Gangaraju,Marisa B. Marques,X. Long Zheng
THROMBOSIS AND HEMOSTASIS
von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD
Clinical Trials & Observations
Ferdows Atiq,Lisette M. Schütte,Agnes E. M. Looijen,Johan Boender,Marjon H. Cnossen,Jeroen Eikenboom,Moniek P. M. de Maat,Marieke J. H. A. Kruip,Frank W. G. Leebeek
TRANSPLANTATION
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Clinical Trials & Observations
Emma Das-Gupta,Kirsty J. Thomson,Adrian J. C. Bloor,Andrew D. Clark,Stephen Mackinnon,Irfan Kayani,Laura Clifton-Hadley,Pip Patrick,Nadjet El-Mehidi,Anthony Lawrie,Amy A. Kirkwood,Nigel H. Russell,David C. Linch,Karl S. Peggs
-
Cover Image
Cover Image
COVER FIGURE
Bioengineered hemophilia A–specific factor VIII (FVIII)–secreting vascular networks in hemophilic mice. Grafts were prepared with human hemophilia A–specific induced pluripotent stem cell–derived endothelial cells that were genetically engineered to overexpress full-length F8. Next, grafts were transplanted subcutaneously into immunodeficient hemophilic mice. After 7 days in vivo, immunofluorescence staining of the explanted grafts revealed the presence of human vessels expressing FVIII (green). Human lumens were stained by h-CD31 (red) and nuclei were stained by DAPI (blue). See the article by Neumeyer et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals